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ABSTRACT 25 
BACKGROUND: The reported incidence of venous thromboembolism (VTE) 26 
in patients with nephrotic syndrome (NS) varies widely, as does the approach 27 
to prophylactic anticoagulation. We aimed to assess the incidence of VTE in 28 
patients with primary NS in order to inform a sample size calculation to 29 
determine if a future clinical trial will ever be feasible. 30 
METHODS: All adults undergoing native renal biopsy for NS between 2008 31 
and 2013 yielding a diagnosis of primary glomerulonephritis were identified. 32 
Baseline serum albumin, urine protein:creatinine ratio, estimated glomerular 33 
filtration rate, date of biopsy and histological diagnosis were recorded. 34 
Episodes of objectively verified VTE were identified using the electronic 35 
patient record. Sample size calculations were performed based on 2 36 
independent samples with a dichotomous outcome and to achieve a power of 37 
80% and p <0.05.  38 
RESULTS: 206 patients were included, of which 60% were male and mean 39 
age at biopsy was 55 years (standard deviation 19). Median follow-up was 2.9 40 
years (inter-quartile range (IQR) 1.6-4.7). Fourteen (6.8%) patients suffered 41 
VTE. Median time to diagnosis of VTE from renal biopsy was 36 days (IQR -42 
22 to 178), with 6 VTEs occurring prior to biopsy and 1 during remission. In a 43 
total of 270 patient years of NS there were 7 VTE that could potentially have 44 
been avoided if anticoagulation was given for the duration of NS, i.e. 2.6% risk 45 
per year of NS; this risk was highest for patients with minimal change 46 
nephropathy at 13.3% per year of NS, compared to 0.65% per year of NS for 47 
those with idiopathic membranous nephropathy. Assuming a 75% reduction in 48 
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the incidence of VTE with prophylactic anticoagulation, 972 participants would 49 
be required for a future clinical trial to have 80% power.  50 
CONCLUSIONS: Patients with primary NS are at an increased risk of VTE. 51 
The timing of VTE means that only half of episodes would be targeted by 52 
prophylactic anticoagulation. Given the low frequency of events, a well-53 
powered clinical trial would be challenging to achieve.  54 
 55 
56 
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INTRODUCTION 57 
 58 
Patients with nephrotic syndrome (NS) due to primary renal diseases are at 59 
an increased risk of venous thromboembolism (VTE). However, the reported 60 
incidence of VTE in patients with NS varies widely from 7–50%[1]. These 61 
figures are often based on historical data, with series that differ in their 62 
inclusion criteria and commonly include asymptomatic thrombi[1].The risk is 63 
reported to be highest in patients with idiopathic membranous nephropathy 64 
(IMN),[2] severe hypoalbuminaemia[3], and early in the course of NS - 65 
particularly within the first 6 months from diagnosis[1,4]. 66 
 67 
In order to reduce the morbidity and mortality of VTE in patients with NS, 68 
international guidelines advise consideration of prophylactic anticoagulation 69 
for high risk patients for the duration of NS[5]. There are no prospective 70 
randomised clinical trials that examine the use of prophylactic anticoagulation 71 
in patients with NS. Furthermore, these patients may have a high prevalence 72 
of recognised risk factors for bleeding such as chronic kidney disease (CKD) 73 
(estimated glomerular filtration rate (eGFR) <30 ml/min/1.73m2 ), hypertension 74 
and anaemia[6,7]. The decision to start anticoagulation is therefore based on 75 
clinician judgement, balancing the risk of thrombosis versus the risk of 76 
bleeding.  77 
 78 
In the absence of trial evidence, an accurate description of the risk of clinically 79 
significant VTE in NS is crucial to assist clinicians in their decision-making. 80 
Given the advances in radiological tests for diagnosis of VTE and also new 81 
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approaches to remission induction, existing data from cohorts that pre-date 82 
these developments may not be applicable to the modern clinical era. To date, 83 
the practice in our centre has been not to anticoagulate patients with NS 84 
routinely, unless there is clinical evidence of symptomatic VTE. We aimed to 85 
assess the incidence of symptomatic VTE within our population of patients 86 
with NS due to biopsy-proven primary glomerulonephritis, in order to inform a 87 
sample size calculation to determine if a future clinical trial will ever be 88 
feasible. 89 
 90 
METHODS 91 
All adult patients undergoing native renal biopsy for the primary indication of 92 
NS between 2008 and 2013 in the Glasgow Renal & Transplant Unit were 93 
identified. This unit serves a defined population of 1.6 million, with the 94 
predominant ethnic group being white. 95 
 96 
Baseline serum albumin (sAlb), urine protein:creatinine ratio (uPCR), eGFR 97 
(calculated by Modified Diet in Renal Disease (MDRD4) formula[8]), date of 98 
biopsy and histological diagnosis were recorded. We excluded patients who 99 
did not have a diagnosis of primary glomerulonephritis. Patients with 100 
membranous nephropathy were excluded if it was secondary to an 101 
established causative factor – patients are routinely screened for viral 102 
hepatitis and systemic lupus erythematosus at presentation and undergo full 103 
clinical examination, chest x-ray and other investigations to exclude 104 
secondary causes as appropriate.   105 
 106 
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Data were also collected regarding aspirin, anticoagulation and 107 
immunosuppressive therapy during follow-up. Bleeding complications were 108 
recorded. 109 
 110 
Using the electronic patient record, which includes automated downloads of 111 
all radiological reports and clinical correspondence, incidence of objectively 112 
confirmed VTE at any site was determined. VTE were diagnosed by Doppler 113 
ultrasound, computed tomography with contrast, ventilation-perfusion imaging 114 
or post-mortem pathological examination. Patients were not prospectively 115 
screened for VTE but investigated on the basis of clinical suspicion. VTE 116 
occurring more than1 year prior to biopsy and episodes of arterial thrombosis 117 
were not included. Incidence of renal replacement therapy (RRT) and cause 118 
of death were also recorded. 119 
 120 
Follow-up was deemed as the latest date of contact with renal services in a 121 
setting that would allow identification of significant VTE (mostly out-patient 122 
clinic review). Patients who suffered VTE were censored from the date that 123 
VTE was confirmed. Patients who required RRT were not censored from 124 
follow-up, but were censored for the purposes of calculating duration of NS. If 125 
no information was available regarding cause of death, the patients were 126 
censored at the time of last renal review. 127 
 128 
Total time in NS was calculated for each patient based on partial remissions 129 
and relapses during follow-up.  Time to first partial remission was calculated 130 
based on the date of the 2nd consecutive uPCR<300mg/mmol and 131 
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sAlb>30g/L. Relapse was defined as the first date after remission on which 132 
the patient had a 2nd consecutive uPCR >300mg/mmol and sAlb <30g/L, or 133 
the date on which the patient began treatment for a clinical diagnosis of 134 
relapse of NS.  135 
 136 
Ethics 137 
Data were accessed via the West of Scotland Electronic Renal Patient 138 
Record, which is the primary clinical record for all patients attending 139 
secondary care renal services in our centre. As an evaluation of current 140 
clinical practice using routinely collected patient data, ethical approval was not 141 
required.  142 
 143 
Data analysis 144 
Baseline demographics were compared using Student t-test, Mann-Whitney 145 
U-test, and χ2 test as appropriate, with mean values and standard deviation 146 
reported for normally distributed data, and median plus inter-quartile range for 147 
non-parametric data. Relative risk (RR) was calculated using binary logistic 148 
regression. Reported RR and the associated 95% confidence intervals (95% 149 
CIs) express the risk of death based on the achievement of remission. 150 
Analyses were undertaken using IBM SPSS (version 22, New York) with 151 
additional tables and figures created using Microsoft Excel 2011 Software 152 
(Microsoft, USA). Sample size calculations were performed based on 2 153 
independent samples with a dichotomous outcome and to achieve a power of 154 
80% and p <0.05.[9] 155 
 156 
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RESULTS 157 
Demographics 158 
A total of 1178 patients underwent first renal biopsy between 2008 and 2013, 159 
for which NS was the primary indication in 291. In 85 patients, NS was 160 
secondary to systemic disease (diabetes, lupus, secondary membranous or 161 
amyloidosis) and these patients were excluded from further analyses. Of the 162 
remaining 206 patients with NS secondary to biopsy-proven primary 163 
glomerular disease, 60% were male, mean age at biopsy was 55 (SD 19) 164 
years, mean eGFR 72 (SD 40) ml/min/1.73m2, median uPCR 812 mg/mmol 165 
(IQR 535-1200) and mean sAlb 19.1g/l (SD 7.1) (table 1). Histological 166 
diagnoses made were idiopathic membranous nephropathy (IMN) (38%), 167 
minimal change nephropathy (MCN) (26%), focal segmental 168 
glomerulosclerosis (FSGS) (18%), IgA nephropathy (IgAN) (11%) and 169 
mesangiocapillary glomerulonephritis (MCGN) (7%). 170 
 171 
Median follow-up was 2.9 years (IQR 1.6-4.7). The median duration of NS 172 
was 0.79 years (IQR 0.3-2.0) years; however, this varied for different 173 
histological diagnoses (table 2). 22 (10.7%) patients developed end-stage 174 
renal failure requiring long-term RRT. Median time to RRT from biopsy in 175 
these patients was 1.5 years (IQR 0.3-2.2). 176 
 177 
Incidence of VTE  178 
Fourteen (6.8%) patients had VTE, of whom 7 had IMN, 5 MCN, 1 IgAN and 1 179 
FSGS. 65% were male and, at time of diagnosis of VTE, mean age was 53.6 180 
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(SD 14) years, mean eGFR 61.2 (SD 32) ml/min/1.73m2, median uPCR 750 181 
(IQR 404-1453) mg/mmol and mean serum albumin 22.8 (SD 10.8) g/l. 182 
There was no significant difference in the mean age (p=0.67), sAlb at biopsy 183 
(p=0.5) or median uPCR at biopsy (p=0.9) between those who suffered a VTE 184 
and those who did not. Nine VTEs occurred in the 123 patients with a sAlb 185 
<20 at biopsy (7.3%) and 5 VTEs occurred in 83 patients with a sAlb ≥20 at 186 
biopsy (6.0%) (p=0.7). 187 
 188 
Site and timing of VTE 189 
The sites of VTE were pulmonary (n=8), leg deep vein (n=3), renal vein (n=2) 190 
and portal vein (n=1). Median time to diagnosis of VTE from renal biopsy was 191 
36 days (IQR -41 to 178). Six patients had a diagnosis of VTE before biopsy, 192 
with only 1 of these 6 patients being known to renal services at time of VTE.  193 
Excluding VTE pre-biopsy (n=6), median time to VTE was 177 days (99-223 194 
days) with 7 of the 8 VTEs occurring within the first year after biopsy. In total, 195 
270 patient years of NS post-biopsy were observed, during which time there 196 
were 8 VTEs; this equated to a 3.0% risk of VTE per year of NS post-biopsy. 197 
One of the 8 patients suffered a VTE (PE) 17 days after achieving remission 198 
from MCN. The incidence of VTE that could potentially be avoided by routine 199 
anticoagulation during periods of NS is therefore 2.6% per year of NS (figure 200 
1). 201 
 202 
VTE by histological diagnosis 203 
The incidence of VTE varied with histological diagnosis. 7 of the 79 patients 204 
with IMN had VTE over a cumulative 155 years of NS, equating to 4.5% risk 205 
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per year of NS. However, this fell to 0.65% when pre-biopsy VTE were 206 
excluded. Patients with MCN had a higher risk, with 5 VTE in 54 patients over 207 
30 years of NS leading to a 16.7% risk per year of NS. The rate of VTE in 208 
patients with MCN that could potentially be prevented by prophylactic 209 
anticoagulation during NS was 13.3% per year of NS. Patients with 210 
histological diagnoses that were neither IMN nor MCN, had an overall risk of 211 
2.4% for each year of NS. 212 
 213 
Medications 214 
Fifteen patients in the non-VTE group were prescribed oral anticoagulation (7 215 
atrial fibrillation (AF), 3 historical VTE, 2 left ventricular mural thrombus post-216 
myocardial infarction, 1 for arterio-venous graft patency, 1 femoral artery 217 
thrombosis, and 1 brachial artery thrombosis). Eight patients were on 218 
anticoagulation prior to biopsy and continued this during follow-up, 7 were 219 
started during follow-up, of whom 6 were already in remission from NS. No 220 
patients were prescribed anticoagulation as primary prophylaxis of VTE due to 221 
NS. During follow-up, 70 patients were prescribed aspirin of which 3 (4.3%) 222 
developed VTE. There was no difference in the incidence of VTE between 223 
patients who were prescribed aspirin or not (p=0.3). 124 patients (60%) 224 
received immunosuppressive medications during follow-up. 58 of these 225 
patients received steroid monotherapy and 48 received steroids in conjunction 226 
with a calcineurin inhibitor. In addition, 26 patients received 227 
cyclophosphamide. VTE rates were higher in those who were prescribed 228 
immunosuppression compared to those who were not (p=0.04). 229 
 230 
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 231 
Bleeding complications 232 
No patient who was anticoagulated for a VTE suffered a bleeding 233 
complication. Of the remaining patients, 7 (3.4%) experienced episodes of 234 
major bleeding, 6 of which were gastrointestinal bleeding.  235 
 236 
Survival  237 
Thirty-nine (19%) patients died during follow-up. Two patients had PE listed 238 
on their death certificate and were included in analyses as having experienced 239 
a VTE. Of the remaining patients, 9 died from infective causes (of which 5 240 
were bronchopneumonia), 8 died from CKD [5 declined/withdrew from RRT, 1 241 
pulmonary oedema despite RRT in the context of acute kidney injury and an 242 
acutely ischaemic limb, 1 refractory nephrotic syndrome with recurrent 243 
infections, 1 details unknown], 5 from metastatic malignancy, 3 chronic lung 244 
disease, 1 heart failure, 1 stroke, 1 sigmoid volvulus, 1 acute intestinal 245 
pneumonitis, 1 neurological complications of action myoclonus renal 246 
syndrome  and 1 patient suffered sudden cardiac death (no post-mortem).  247 
A further 2 patients had incomplete information regarding their cause of death 248 
but are documented as having acute respiratory symptoms prior to their 249 
death, 1 of whom had definitive imaging to exclude VTE. For 4 patients, there 250 
was no information available about cause of death; all were still nephrotic at 251 
time of death. Failure to reach remission was an indicator of poor prognosis, 252 
with a five fold increase in the risk of death compared to patients who 253 
achieved at least partial remission (RR 5.23; 95% CI 2.89-9.45).] 254 
 255 
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Sample size required for a randomised trial 256 
If a 75% reduction in the incidence of VTE with prophylactic anticoagulation is 257 
predicted, a randomised trial would require 972 patients to have 80% power 258 
and alpha 0.05. The 200 eligible patients in this study (6 patients had VTE 259 
before biopsy and would have been excluded from a trial) were recruited from 260 
a population of 1.6 million over 6 years, indicating an annual incidence of 2.1 261 
new cases per 100,000 patients. Accounting for an exclusion rate of 20%, it 262 
would require 10 large centres (serving populations >1.6 million) to recruit 263 
patients over 3 years, with subsequent follow-up for 3 years, to achieve this 264 
power, assuming a similar ratio of histological diagnoses and remission rates 265 
as observed in our cohort. If, however, anticoagulation were estimated only to 266 
reduce VTE rate by 50% then a trial would require a sample size of 2618 to 267 
have the same power. If the 4 patients who died of unknown cause of death 268 
are counted as having had a VTE and the estimated reduction in VTE rate is 269 
maintained at 75%, a trial would require 610 participants to have 80% power 270 
and alpha 0.05 271 
 272 
DISCUSSION  273 
This is the largest series investigating the incidence of VTE in patients with 274 
NS due to biopsy-proven primary glomerulonephritis in the modern clinical 275 
era. The overall incidence of clinically significant VTE is 6.8%, with the risk 276 
highest early in the course of NS. However, we highlight that almost half of 277 
these VTE could not have been prevented with prophylactic anticoagulation 278 
as they occurred prior to achieving a renal diagnosis. Furthermore, by 279 
analysing risk according to duration of NS, we have identified a previously 280 
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unrecognised higher risk of VTE in patients with MCN, than IMN, during the 281 
period(s) of NS. Overall, the low incidence of events in a population of 282 
patients with the relatively rare condition of NS due to primary 283 
glomerulonephritis means that a definitive clinical trial is unlikely to be 284 
performed.  285 
 286 
Incidence of VTE 287 
The incidence of VTE in our study is consistent with the two largest reported 288 
cohorts, in which the rate of clinically significant VTE was found to be 7% and 289 
7.9%, respectively[2,3]. However, both these studies included historical data 290 
for patients from the same registry that dated back to 1974, with Lionaki et al 291 
also using patients from as far back as 1969. NS was not an inclusion criterion 292 
in these studies, which may explain the association between the severity of 293 
hypoalbuminaemia and the risk of VTE that was observed in these patients 294 
but not identified in our study. Interestingly, in our cohort, the incidence of 295 
post-biopsy VTE that anticoagulation may prevent was 2.6% per year of NS, 296 
but if anticoagulation were stopped at normalisation of serum albumin (as is 297 
recommended in the KDIGO guidelines[5]), rather than at remission, the 298 
incidence would be 1.85% with a further 1 VTE per 100 patients occurring off 299 
treatment. One patient was diagnosed with PE 17 days following complete 300 
remission from MCN. It is possible that this could have been prevented by 301 
prophylactic anticoagulation if the patient actually developed a DVT during NS 302 
(which later emoblised). 303 
 304 
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The incidence of VTE within the general population and in patients with CKD 305 
without NS is already established,[12–14] and allows comparison of risk with 306 
these results. Patients with CKD 3 or 4 have been shown to have an 307 
incidence of VTE of 4.5 per 1000 patient years, which is approximately twice 308 
that of the general population.[13] 46% of patients in our study had an eGFR 309 
<60ml/min/1.73m2 at time of biopsy but the overall incidence of VTE in our 310 
cohort was still higher at 12.4 VTE per 1000 patient years. 311 
 312 
Timing of VTE 313 
We found the risk of VTE to be highest early in the course of NS with a 314 
median time to VTE of 37 days from renal biopsy (177 days if VTEs prior to 315 
renal diagnosis are excluded). This may be partly explained by a reduction in 316 
thrombotic risk in patients who enter remission - 72% of our cohort achieved 317 
at least transient remission. 33% of those who had VTE experienced it as part 318 
of their NS presentation highlighting the importance of checking for NS in 319 
patients who present with VTE[10].  320 
 321 
Risk of VTE by type of glomerulonephritis 322 
We found a greater risk of VTE in patients with IMN and MCN when compared 323 
to other histological types. NS remission rates were highest in MCN (89%) 324 
and lowest in IMN (63%). While the thrombotic risk of IMN has been reported 325 
previously,[1,2,11]  the risk associated with MCN is under-recognised. The 326 
proportion of VTE that could potentially be prevented with prophylactic 327 
anticoagulation was higher in MCN compared to IMN, presumably due to the 328 
more insidious onset of IMN allowing VTE to occur prior to renal diagnosis. In 329 
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fact, per year of NS patients with IMN had the lowest rate of VTE that would 330 
be targeted by prophylactic anticoagulation. The combination of high 331 
thrombotic risk and short duration of NS means that patients with MCN 332 
arguably have the most to benefit from anticoagulation, in that the frequent 333 
relapse rate means these patients could be anticoagulated for short durations 334 
(reducing their cumulative bleeding risk on anticoagulant) but still covering the 335 
periods of greatest thrombotic risk (i.e. early in the course of NS).  However, 336 
this would require anticoagulation to be started shortly after renal biopsy, and 337 
also re-started during relapses (1 patient suffered first VTE during 4th relapse). 338 
The MCN sub-group in our cohort is relatively small and therefore this 339 
observation should be validated in other cohorts to confirm it.  340 
 341 
 342 
Prophylactic anticoagulation – sample size calculation for randomised 343 
controlled trial 344 
There are no randomised controlled trials to support the use of prophylactic 345 
anticoagulation in patients with NS. One prospective study gave prophylactic-346 
dose low molecular weight heparin (Enoxaparin 40mg) to 30 patients with NS, 347 
and after a median follow-up of 13 months no thrombi were identified.[15] A 348 
further retrospective study from a centre in which routine practice is to offer 349 
VTE prophylaxis in the form of aspirin if sAlb 20-30g/L, and prophylactic dose 350 
LMWH or low dose warfarin if sAlb <20g/L, found no VTE in 143 patients 351 
established on therapy for >1 week with a median follow-up of 2.9 years.[16] 352 
There were 2 episodes of VTE occurring within the first week of treatment and 353 
there were 3 episodes of haemorrhage requiring treatment. They also found a 354 
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high incidence of VTE (7.5% of all patients) occurring before diagnosis. In our 355 
cohort, aspirin alone is not associated with a lower risk. 356 
 357 
The true reduction in VTE risk that can be expected in patients with NS 358 
undergoing anticoagulation is not known. The estimation of a 75% reduction in 359 
VTE risk with prophylactic anticoagulation used in our sample size calculation 360 
is likely to be optimistic. Despite this, and accepting 80% power, the required 361 
sample size would still be challenging to recruit, especially given the relative 362 
rarity of the condition and the expected high prevalence of exclusion criteria 363 
(e.g. bleeding tendency). The risk of VTE in NS is similar to the risk of VTE in 364 
patients with some active cancers,[17] in whom routine  anticoagulation is not 365 
currently recommended.[18] In contrast, it is also similar to the risk of stroke in 366 
patients with atrial fibrillation (a CHA2DS2-VASc score of 2 carries a risk of 367 
stroke of 2.2% per year[19]) in whom anticoagulation is recommended.[20] It 368 
is unknown if patients with nephrotic syndrome would be at an increased risk 369 
of bleeding. Independent risk factors for bleeding on anticoagulation include 370 
renal disease[6,7], hypertension[6,7] and anaemia[6], all of which may be  371 
more prevalent in a population with CKD, but were not common in our cohort 372 
with only 13% having an eGFR < 30 ml/min/1.73m2and an overall mean 373 
haemoglobin of 13 g/dL. 374 
 375 
Nephrotic syndrome and mortality rate 376 
Overall, the mortality rate was high in this study, with 19% of the cohort having 377 
died at a median follow-up of 3 years. Two deaths were directly attributed to 378 
PE. This is the first study to report deaths in this context and the mortality rate 379 
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associated with NS is not widely acknowledged. Our data demonstrate that 380 
achieving even partial remission is associated with a reduced risk of death. 381 
We cannot exclude the possibility that an unrecognised burden of VTE might 382 
have contributed to mortality. 383 
 384 
Limitations and strengths 385 
This study has a number of limitations. Primarily, the small number of events 386 
limits the conclusions that can be drawn. It is a cohort from a single-centre, 387 
albeit one which serves a population of 1.6 million. Follow-up was relatively 388 
short; however, in light of the increased frequency of thrombotic events early 389 
in the course of NS, it is likely to be sufficient and is in line with previous 390 
studies. The data have been collected retrospectively via a comprehensive, 391 
prospectively compiled regional electronic patient record that contains 392 
laboratory results, radiology reports, clinical correspondence and medication 393 
records. We are therefore confident that there is a low likelihood that we have 394 
missed episodes of clinically significant VTE. We did not assess the incidence 395 
of arterial thrombus and this has previously been reported to be increased in 396 
patients with NS and may benefit from prophylactic anticoagulation[4,21]. Our 397 
study focused on patients with a histological diagnosis of a primary 398 
glomerulonephritis in whom the main indication for biopsy was NS. Therefore, 399 
our results are not applicable to patients with NS secondary to systemic 400 
diseases, patients with NS for whom a histological diagnosis is not being 401 
pursued and patients who had a different primary indication for biopsy.   402 
 403 
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The study has strengths. It is a cohort of patients exclusively with 404 
histologically-confirmed primary glomerulonephritis. It is set within the modern 405 
clinical era and, as patient inclusion was limited to patients with biopsies 406 
performed in 2008 or after, the results are reflective of a contemporary 407 
approach to the diagnosis and management of NS and VTE. None of our 408 
patients were on anticoagulation for primary prophylaxis of VTE due to NS. 409 
These data therefore illustrate the natural history of VTE risk in patients with 410 
NS in the contemporary clinical era.  411 
 412 
Conclusions 413 
 414 
Our data confirm that patients with primary NS are at increased risk of VTE 415 
compared with the general population and those with CKD. The timing of VTE 416 
means that only half of episodes would be targeted by prophylactic 417 
anticoagulation, greatly reducing any extrapolated benefit. Contrary to existing 418 
guidelines, our data suggest that patients with MCN, rather than IMN, have 419 
the greatest potential benefit to gain from prophylactic anticoagulation. There 420 
remains equipoise regarding the clinical benefit of prophylactic anticoagulation 421 
but the low incidence of events in a population of patients with a relatively rare 422 
condition means that a definitive clinical trial is unlikely to be performed. 423 
 424 
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TABLES 514 
Table 1.Baseline demographics and outcomes in all patients and those who 515 
did and did not suffer venous thromboembolism. 516 
 517 
Demographics All patients VTE Non-VTE p-value 
N= 206 14 (6.8%) 192 
(93.2%) 
 
Male  
N (%) 
60% 65% 60% 0.79 
Mean age at biopsy 
(SD), years 
55 (19) 53 (14) 55 (19) 0.7 
Mean eGFR at 
biopsy 
(SD), ml/min/1.73m2  
72 (40) 61 (32) 62 (40) 0.5 
Median uPCR at 
biopsy 
(IQR), mmol/mol 
812 (535-
1200) 
750 (404-
1453) 
812 (496-
1197) 
0.91 
Mean sAlb at biopsy 
(SD), g/l 
19.1 (7.1) 22.8 (10.8) 18 (7.0) 0.5 
Partial remission 
N (%) 
149 (72%) 9 (64%) 140 (73%) 0.54 
Immunosuppression 
N (%) 
124 (60%) 12 (86%) 112 (58%) 0.04 
RRT 
N (%) 
22 (10.7%) 1 (7.1%) 21 (10.9%) 0.54 
Mortality 
N (%) 
39 (19%) 3 (21%) 36 (19%) 0.73 
Abbreviations: VTE, venous thromboembolism; eGFR, estimated glomerular 518 
filtration rate; uPCR, urinary protein:creatinine ratio; sAlb, serum albumin; 519 
RRT, renal replacement therapy. 520 
 521 
Data are presented as number (n) +percentage, mean+standard deviation 522 
(SD), or median+interquartile range (IQR). Comparison between VTE and 523 
non-VTE groups was made using T-test and Mann-Whitney test as 524 
appropriate, with significance threshold of p=<0.05 525 
 526 
 527 
 528 
529 
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Table 2. Outcomes by histological diagnosis  530 
 IMN MCN FSGS IgA MPGN 
N, (% of total) 79 
(38.3%) 
54 
(26.2%) 
37  
(18%) 
22 
(10.7%) 
14  
(6.8%) 
 Partial remission 
achieved, n (%) 
 
50 (63%) 48 (89%) 24 (65%) 19 (86%) 9 (64%) 
Median duration of 
NS, years, (IQR) 
 
1.76 
(0.79-
2.66) 
0.32 
(0.15-
0.54) 
0.79 
(0.46-
1.84) 
0.57 
(0.24-
1.84) 
0.54 
(0.19-
1.65) 
VTE, n (%) 7 (8.9%) 
 
5 (9.3%) 1 (2.7%) 1 (4.5%) 0 
Proportion of VTE 
which prophylactic 
anticoagulation may 
prevent 
1/7 4/5 1/1 1/1  - 
Survival, n (%) 59 (75%) 
 
51 (94%) 29 (78%) 16 (735) 12 (85%) 
 531 
Abbreviations: IMN, idiopathic membranous nephropathy; MCN, minimal 532 
change nephropathy; FSGS, focal segmental glomerulosclerosis; IgA, IgA 533 
nephropathy; MCGN, mesangiocapillary glomerulonephritis; VTE, venous 534 
thromboembolism;  535 
 536 
Data are presented as number (n) and percentage of total or 537 
median+interquartile range (IQR).  538 
539 
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FIGURES 540 
Figure 1. Summary of the timing of VTE episodes in patients with nephrotic 541 
syndrome, highlighting the limitations of prophylactic anticoagulation.  542 
 543 
